Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 11/20 | 0.45 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.45 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.45 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484501 | 0.92 | KCNH2 (0.43) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL5488058 | 0.88 | MCL1 (0.48) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL5482011 | 0.85 | KDM4E (0.46) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL5482016 | 0.85 | KDM4E (0.46) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL5490373 | 0.85 | KDM4E (0.46) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL5483694 | 0.84 | SCN3A (0.58) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL5481360 | 0.84 | KCNH2 (0.52) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL5481355 | 0.84 | KCNH2 (0.52) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL5481350 | 0.84 | KCNH2 (0.52) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL6064341 | 0.84 | KCNH2 (0.52) | KCNH2SCN3ASCN1ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265244-B2 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-09-04 | — | — | US | claimed |
| EP-1687259-B1 | CYCLOPENTYL DERIVATES | NEWRON PHARM SPA (IT) | 2007-08-08 | — | — | EP | claimed |
| US-20070066688-A1 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-03-22 | — | — | US | claimed |
| EP-1687259-A1 | CYCLOPENTYL DERIVATES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-09 | — | — | EP | claimed |
| WO-2005054178-A1 | CYCLOPENTYL DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1533295-A1 | Cyclopentyl Derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | claimed |
| US-7265244-B2 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-09-04 | — | — | US | disclosed |
| EP-1687259-B1 | CYCLOPENTYL DERIVATES | NEWRON PHARM SPA (IT) | 2007-08-08 | — | — | EP | disclosed |
| US-20070066688-A1 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-03-22 | — | — | US | disclosed |
| EP-1687259-A1 | CYCLOPENTYL DERIVATES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054178-A1 | CYCLOPENTYL DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1533295-A1 | Cyclopentyl Derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066688-A1 | Cyclopentyl derivatives | HCN3, RYR2, KCNN3 | KCNH2 87/4885SCN3A 21/4885SCN1A 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.